TrialJAMA psychiatry2013

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.

Charles L Raison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.